This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bloom Health Partners Valuation

Q: What is the Fair Price of D840 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

D840 (€0.03) is trading below our estimate of [[fair value]] (€7.95)

Is D840 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of D840 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: D840 (€0.03) is trading below our estimate of fair value (€7.95)

Significantly Below Fair Value: D840 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for D840?

Key metric: As D840 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for D840. This is calculated by dividing D840's market cap by their current earnings.
What is D840's PE Ratio?
PE Ratio	1.1x
Earnings	CA$3.58m
Market Cap	CA$3.81m

D840 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does D840's PE Ratio compare to its peers?

The above table shows the PE ratio for D840 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	88.5x
HAEK HAEMATO	9.5x	5.8%	€91.0m
ILM1 Medios	28.5x	47.8%	€366.3m
530057 Vivanza Biosciences	227.6x	n/a	₹166.8m
IS8 ifa systems	n/a	n/a	€6.1m
D840 Bloom Health Partners	1.1x	n/a	€3.8m

Price-To-Earnings vs Peers: D840 is good value based on its Price-To-Earnings Ratio (1.1x) compared to the peer average (55.3x).

Price to Earnings Ratio vs Industry

How does D840's PE Ratio compare vs other companies in the European Healthcare Industry?

3 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	18.2x	27.9%
D840 Bloom Health Partners	1.1x	n/a	US$2.84m

3 Companies		Estimated Growth	Market Cap
Industry Avg.	18.2x	27.9%
D840 Bloom Health Partners	1.1x	n/a	US$2.84m

No more companies

Price-To-Earnings vs Industry: D840 is good value based on its Price-To-Earnings Ratio (1.1x) compared to the European Healthcare industry average (15.6x)

Price to Earnings Ratio vs Fair Ratio

What is D840's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

D840 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	1.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate D840's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sensus Healthcare

US$112.8m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$6.45

4.0%

251.1%

Ship Healthcare Holdings

JP¥194.6b

Engages in the medical, healthcare, welfare, and nursing care businesses worldwide.

5EZ

JP¥12.30

-9.6%

-4.7%

CVS Health

US$68.3b

Provides health solutions in the United States.

CVS

US$52.20

-2.4%

-16.6%